GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » YoY EBITDA Growth

Advanced Oncotherapy (FRA:R3I1) YoY EBITDA Growth : 9.09% (As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Advanced Oncotherapy's YoY EBITDA Growth for the quarter that ended in Jun. 2022 was 9.09%.

Advanced Oncotherapy's EBITDA per Share for the six months ended in Jun. 2022 was €-0.03.


Advanced Oncotherapy YoY EBITDA Growth Historical Data

The historical data trend for Advanced Oncotherapy's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy YoY EBITDA Growth Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.90 26.85 34.18 30.77 5.56

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.61 17.07 -6.45 5.88 9.09

Advanced Oncotherapy YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Advanced Oncotherapy's YoY EBITDA Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY EBITDA Growth (A: Dec. 2021 )
=(EBITDA per Share (A: Dec. 2021 )-EBITDA per Share (A: Dec. 2020 ))/ | EBITDA per Share (A: Dec. 2020 ) |
=(-0.068--0.072)/ | -0.072 |
=5.56 %

Advanced Oncotherapy's YoY EBITDA Growth for the quarter that ended in Jun. 2022 is calculated as:

YoY EBITDA Growth (Q: Jun. 2022 )
=(EBITDA per Share (Q: Jun. 2022 )-EBITDA per Share (Q: Jun. 2021 )) / | EBITDA per Share (Q: Jun. 2021 )) |
=(-0.03--0.033)/ | -0.033 |
=9.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (FRA:R3I1) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines